Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease

Orren Beaty, Melissa M. Hudson, Carol Greenwald, Xiaolong Luo, Lei Fang, Judith A. Wilimas, Elizabeth I. Thompson, Larry E. Kun, Charles B. Pratt

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Purpose: We assessed the cumulative risk of malignancies following treatment for Hodgkin's disease in childhood and adolescence and investigated related patient and treatment characteristics. Patients and Methods: Medical records of 499 Hodgkin's disease patients treated between 1962 and 1993 were reviewed. There were 385 adolescents (≥ 10 years of age at diagnosis) and 114 preadolescents (< 10 years). Most patients (n = 346) were treated with radiation plus multiagent chemotherapy, while 30 received only chemotherapy and 123 only radiation therapy. Radiation doses ranged from 20 to 42 Gy. Results: At a median follow-up duration of 9 years (range, 0.1 to 27.4), 25 patients have had second malignancies: 19 solid tumors, four acute nonlymphoblastic leukemias (ANLLs), 1 non-Hodgkin's lymphoma (NHL), and one chronic myeloid leukemia (CML). Three patients have had a third malignancy. The estimated cumulative risk of second malignancies increased from 1.5% at 5 years to 7.7% at 15 years. All but two of the patients with second malignancies were ≥ 10 years of age at initial diagnosis, which reflects the higher risk among patients treated for Hodgkin's disease as adolescents (P = .01). Second malignancies were more common among female patients (P = .0002), even when those with breast cancer were excluded (P = .007), and in those treated for recurrent Hodgkin's disease (P = .02). Patients with ANLL/NHL were older at diagnosis of Hodgkin's disease than those with solid tumors, (median age, 18.3 v 13.8 years; P = .04). There was no difference between groups treated with radiation therapy alone, chemotherapy alone, or radiation plus multiagent chemotherapy. Conclusion: Adolescents treated for Hodgkin's disease are at greater at risk of second malignancies than younger patients. Overall, adolescent females treated for recurrent Hodgkin's disease appear to be at greatest risk, while preadolescents appear to be protected from this late complication.

Original languageEnglish (US)
Pages (from-to)603-609
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number3
DOIs
StatePublished - Jan 1 1995

Fingerprint

Hodgkin Disease
Second Primary Neoplasms
Neoplasms
Therapeutics
Drug Therapy
Radiation
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Radiotherapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Medical Records
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Beaty, O., Hudson, M. M., Greenwald, C., Luo, X., Fang, L., Wilimas, J. A., ... Pratt, C. B. (1995). Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. Journal of Clinical Oncology, 13(3), 603-609. https://doi.org/10.1200/JCO.1995.13.3.603

Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. / Beaty, Orren; Hudson, Melissa M.; Greenwald, Carol; Luo, Xiaolong; Fang, Lei; Wilimas, Judith A.; Thompson, Elizabeth I.; Kun, Larry E.; Pratt, Charles B.

In: Journal of Clinical Oncology, Vol. 13, No. 3, 01.01.1995, p. 603-609.

Research output: Contribution to journalArticle

Beaty, O, Hudson, MM, Greenwald, C, Luo, X, Fang, L, Wilimas, JA, Thompson, EI, Kun, LE & Pratt, CB 1995, 'Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease', Journal of Clinical Oncology, vol. 13, no. 3, pp. 603-609. https://doi.org/10.1200/JCO.1995.13.3.603
Beaty, Orren ; Hudson, Melissa M. ; Greenwald, Carol ; Luo, Xiaolong ; Fang, Lei ; Wilimas, Judith A. ; Thompson, Elizabeth I. ; Kun, Larry E. ; Pratt, Charles B. / Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 3. pp. 603-609.
@article{72ef527794124149a72c174b83e7be82,
title = "Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease",
abstract = "Purpose: We assessed the cumulative risk of malignancies following treatment for Hodgkin's disease in childhood and adolescence and investigated related patient and treatment characteristics. Patients and Methods: Medical records of 499 Hodgkin's disease patients treated between 1962 and 1993 were reviewed. There were 385 adolescents (≥ 10 years of age at diagnosis) and 114 preadolescents (< 10 years). Most patients (n = 346) were treated with radiation plus multiagent chemotherapy, while 30 received only chemotherapy and 123 only radiation therapy. Radiation doses ranged from 20 to 42 Gy. Results: At a median follow-up duration of 9 years (range, 0.1 to 27.4), 25 patients have had second malignancies: 19 solid tumors, four acute nonlymphoblastic leukemias (ANLLs), 1 non-Hodgkin's lymphoma (NHL), and one chronic myeloid leukemia (CML). Three patients have had a third malignancy. The estimated cumulative risk of second malignancies increased from 1.5{\%} at 5 years to 7.7{\%} at 15 years. All but two of the patients with second malignancies were ≥ 10 years of age at initial diagnosis, which reflects the higher risk among patients treated for Hodgkin's disease as adolescents (P = .01). Second malignancies were more common among female patients (P = .0002), even when those with breast cancer were excluded (P = .007), and in those treated for recurrent Hodgkin's disease (P = .02). Patients with ANLL/NHL were older at diagnosis of Hodgkin's disease than those with solid tumors, (median age, 18.3 v 13.8 years; P = .04). There was no difference between groups treated with radiation therapy alone, chemotherapy alone, or radiation plus multiagent chemotherapy. Conclusion: Adolescents treated for Hodgkin's disease are at greater at risk of second malignancies than younger patients. Overall, adolescent females treated for recurrent Hodgkin's disease appear to be at greatest risk, while preadolescents appear to be protected from this late complication.",
author = "Orren Beaty and Hudson, {Melissa M.} and Carol Greenwald and Xiaolong Luo and Lei Fang and Wilimas, {Judith A.} and Thompson, {Elizabeth I.} and Kun, {Larry E.} and Pratt, {Charles B.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1200/JCO.1995.13.3.603",
language = "English (US)",
volume = "13",
pages = "603--609",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease

AU - Beaty, Orren

AU - Hudson, Melissa M.

AU - Greenwald, Carol

AU - Luo, Xiaolong

AU - Fang, Lei

AU - Wilimas, Judith A.

AU - Thompson, Elizabeth I.

AU - Kun, Larry E.

AU - Pratt, Charles B.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Purpose: We assessed the cumulative risk of malignancies following treatment for Hodgkin's disease in childhood and adolescence and investigated related patient and treatment characteristics. Patients and Methods: Medical records of 499 Hodgkin's disease patients treated between 1962 and 1993 were reviewed. There were 385 adolescents (≥ 10 years of age at diagnosis) and 114 preadolescents (< 10 years). Most patients (n = 346) were treated with radiation plus multiagent chemotherapy, while 30 received only chemotherapy and 123 only radiation therapy. Radiation doses ranged from 20 to 42 Gy. Results: At a median follow-up duration of 9 years (range, 0.1 to 27.4), 25 patients have had second malignancies: 19 solid tumors, four acute nonlymphoblastic leukemias (ANLLs), 1 non-Hodgkin's lymphoma (NHL), and one chronic myeloid leukemia (CML). Three patients have had a third malignancy. The estimated cumulative risk of second malignancies increased from 1.5% at 5 years to 7.7% at 15 years. All but two of the patients with second malignancies were ≥ 10 years of age at initial diagnosis, which reflects the higher risk among patients treated for Hodgkin's disease as adolescents (P = .01). Second malignancies were more common among female patients (P = .0002), even when those with breast cancer were excluded (P = .007), and in those treated for recurrent Hodgkin's disease (P = .02). Patients with ANLL/NHL were older at diagnosis of Hodgkin's disease than those with solid tumors, (median age, 18.3 v 13.8 years; P = .04). There was no difference between groups treated with radiation therapy alone, chemotherapy alone, or radiation plus multiagent chemotherapy. Conclusion: Adolescents treated for Hodgkin's disease are at greater at risk of second malignancies than younger patients. Overall, adolescent females treated for recurrent Hodgkin's disease appear to be at greatest risk, while preadolescents appear to be protected from this late complication.

AB - Purpose: We assessed the cumulative risk of malignancies following treatment for Hodgkin's disease in childhood and adolescence and investigated related patient and treatment characteristics. Patients and Methods: Medical records of 499 Hodgkin's disease patients treated between 1962 and 1993 were reviewed. There were 385 adolescents (≥ 10 years of age at diagnosis) and 114 preadolescents (< 10 years). Most patients (n = 346) were treated with radiation plus multiagent chemotherapy, while 30 received only chemotherapy and 123 only radiation therapy. Radiation doses ranged from 20 to 42 Gy. Results: At a median follow-up duration of 9 years (range, 0.1 to 27.4), 25 patients have had second malignancies: 19 solid tumors, four acute nonlymphoblastic leukemias (ANLLs), 1 non-Hodgkin's lymphoma (NHL), and one chronic myeloid leukemia (CML). Three patients have had a third malignancy. The estimated cumulative risk of second malignancies increased from 1.5% at 5 years to 7.7% at 15 years. All but two of the patients with second malignancies were ≥ 10 years of age at initial diagnosis, which reflects the higher risk among patients treated for Hodgkin's disease as adolescents (P = .01). Second malignancies were more common among female patients (P = .0002), even when those with breast cancer were excluded (P = .007), and in those treated for recurrent Hodgkin's disease (P = .02). Patients with ANLL/NHL were older at diagnosis of Hodgkin's disease than those with solid tumors, (median age, 18.3 v 13.8 years; P = .04). There was no difference between groups treated with radiation therapy alone, chemotherapy alone, or radiation plus multiagent chemotherapy. Conclusion: Adolescents treated for Hodgkin's disease are at greater at risk of second malignancies than younger patients. Overall, adolescent females treated for recurrent Hodgkin's disease appear to be at greatest risk, while preadolescents appear to be protected from this late complication.

UR - http://www.scopus.com/inward/record.url?scp=0028923241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028923241&partnerID=8YFLogxK

U2 - 10.1200/JCO.1995.13.3.603

DO - 10.1200/JCO.1995.13.3.603

M3 - Article

C2 - 7884422

AN - SCOPUS:0028923241

VL - 13

SP - 603

EP - 609

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -